Could skipping chemo speed up bladder cancer surgery without harm?

NCT ID NCT05776758

NEW Ongoing Disease control Sponsor: Regina Elena Cancer Institute Source: ClinicalTrials.gov ↗

First seen Aug 17, 2026 · Last updated Aug 17, 2026

Summary

This phase 3 trial asks whether removing the bladder right away is as effective as giving chemotherapy first, for patients with muscle-invasive bladder cancer who have no visible tumor left after a thorough biopsy. About 236 adults will be randomly assigned to either surgery alone or chemo plus surgery. The goal is to see if skipping chemo avoids unnecessary side effects and delays without reducing survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cisplatin-based neoadjuvant chemotherapy
What this could lead to: If skipping chemo proves as effective, patients could avoid unnecessary side effects and get surgery sooner.
What could go wrong: The trial is still recruiting and results are not yet available. Skipping chemo might slightly increase the risk of cancer returning, and the study only applies to a specific patient group.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHEMOTHERAPY EFFECT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chemotherapy-induced toxicity infiltrating bladder urothelial carcinoma Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHEMOTHERAPY EFFECT MUSCLE-INVASIVE BLADDER CARCINOMA SURGERY

Contacts and locations

Locations

Riccardo Mastroianni

Rome, 00144, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.